Navigation Links
Bronchiectasis in Medical News

Transave Completes Enrollment in Arikace(TM) Phase II Bronchiectasis Study

Presently No Approved Treatments MONMOUTH JUNCTION, N.J., April 21 /PRNewswire/ -- Transave, Inc., today reported completion of patient enrollment in a Phase II study evaluating the safety and efficacy of Arikace(TM) (liposomal amikacin for inhalation) in non-cystic fibrosis (CF) bronchiect...

Pharmaxis to Expand Manufacturing Capacity

...eloping Bronchitol for the treatment of diseases including cystic fibrosis, bronchiectasis and chronic bronchitis. Construction of the key manufacturing equipment co...clude: Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD) and PXS64 for the treatmen...

Arsenic in Drinking Water Predisposes Children To Lung Cancer in Later Life

...life. It was found that the risk of dying from bronchiectasis was 46 times more than normal if the child's mothe... than in the rest of Chile. The risk of death from bronchiectasis was 46 times greater. "In all my career, these are... these the highest death rates for lung cancer and bronchiectasis ever discovered among young adults, but they are a...
Bronchiectasis in Medical Technology

12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis

SYDNEY, Australia, Aug. 20 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the Phase 3 clinical trial evaluating the long term safety of Bronchitol in subjects with bronchiectasis has concluded with no serious adverse events attri...

Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)

...lung infections in cystic fibrosis (CF) and non-CF bronchiectasis patients. Transave announced today that the award...uated in the treatment of non-CF patients who have bronchiectasis with Pseudomonas lung infections. In the bronchiectasis trial, 64 adult patients were randomized 2:1 to tw...

Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial

...ic respiratory and immune disorders. Its development pipeline of products includes Aridol for the diagnosis of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), PXS25 for the treatment of lung fibrosis and PXS4159 for asthma. Founded in 1998, Pharmaxis is liste...

Pharmaxis Announces New Drug Application Submission for Aridol(TM)

...c respiratory and immune disorders. Its development pipeline of products includes Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), PXS25 for the treatment of lung fibrosis and PXS4159 for asthma. Founded in 1998, Pharmaxis is ...

ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia

...at more than 600,000 people in the major pharmaceutical markets suffer from bronchiectasis and Pharmaxis expects Bronchitol to be the first targeted medication for th...l need. In Australia, it is believed that more than 18,000 people live with bronchiectasis and over 70% are moderately or severely incapacitated by their condition. ...

Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins

...4_CF302_Commences.pdf . Pharmaxis is developing Bronchitol as a treatment to improve mucus clearance in the lungs of patients with cystic fibrosis, bronchiectasis and chronic obstructive airway diseases. Bronchitol is a patented, inhalable dry powder formulation of mannitol that can be administered by a convenie...

Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial

...n the phase 3 registration trial of Bronchitol for bronchiectasis via the Special Protocol Assessment process. The...h internationally renowned experts in the field of bronchiectasis and will be a randomized, placebo controlled, doub...Phase III study to be undertaken for Bronchitol in bronchiectasis and follows the completion of a successful shorter...

Pharmaxis Long-Term Safety Study of Bronchitol Completes

...ting the safety of Bronchitol in 100 subjects with bronchiectasis has completed. This 12-month treatment period wa...le in the major pharmaceutical markets suffer from bronchiectasis and Pharmaxis expects Bronchitol to be the first t...tal U.S. medical care expenditure is US$13,000 per bronchiectasis patient, double that of patients without the disor...
Bronchiectasis in Medical Definition

Pathology

...r abscess - Vocal fold nodule - Laryngospasm Chronic lower respiratory diseases Emphysema - COPD - Asthma - Status asthmaticus - bronchiectasis Lung diseases due to external agents Coalworker's pneumoconiosis - Pneumoconiosis - Silicosis - Bauxite fibrosis - Berylliosis - S...
Bronchiectasis in Medical Dictionary

Bronchiectasis

Bronchiectasis is a disease that causes localized, irreversible dilation of part of the bronchial tree. It is classified as an obstructive lung disease, along with bronchitis and cystic fibrosis. Involved bronchi are dilated,... Bronchiectasis is an irreversible widening (dilation) ...

Respiratory disorders

...om leading medical centers. ... Welcome to the Respiratory Disorders Forum ... Respiratory Disorders / COPD / Occupational Lung Diseases / bronchiectasis ... While usually classified as a respiratory disorder , it is the pancreas which is ... Exclusive directory of alternative medicine, holisti...

Lung infection

...ncluding treatment and ... Infections . Kidney and Urinary Tract Disorders. Liver and ... in the course of lung infections help to prevent bronchiectasis or reduce its severity. ... Although CMV infection is usually harmless, it can cause severe disease in ... symptoms do appear, they include ...
Bronchiectasis in Biological Technology

Regulatory Path for Bronchitol in Bronchiectasis

SYDNEY, Australia, May 1 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (AXS: PSX; Nasdaq: PXSL) today announced that it has agreed with advice from the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 trial of the company's mucus clearing agent, Bronchitol, in patients w...

Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria

...letion of enrollment in two additional Phase II trials including a study where ARIKACE is being evaluated in the treatment of non-CF patients who have bronchiectasis with Pseudomonas lung infections and a second trial in U.S. CF patients with Pseudomonas lung infections. ARIKACE has been granted orph...

Pharmaxis Builds Senior Management Team

...c respiratory and immune disorders. Its development pipeline of products includes Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), PXS25 for the treatment of lung fibrosis and PXS4159 for asthma. Founded in 1998, Pharmaxis is liste...

Chronic Lung Disease - Axentis Pharma Attracts Investment Interest

...domonas aeruginosa. Chronic inflammations then cause lung functions to become blocked. In addition to the breakdown of lung tissue, this also leads to bronchiectasis and lung failure. For further information, please contact: Axentis Pharma AG Limmatquai 138 8001 Zurich Switzerland T: +4...

Pharmaxis Research Programs Highlighted at European Respiratory Society Congress

...nfectious lung diseases including tuberculosis -- A randomized, placebo-controlled trial of inhaled mannitol(Bronchitol) in patients with bronchiectasis -- Cough and airway hyperresponsiveness -- A comparison of inhaled mannitol (Aridol), methacholine provocation and eucapnic voluntary h...

Transave, Inc. Secures $12.5 Million in New Financing

...linical trial in a second area of high unmet need: bronchiectasis patients who have pseudomonas lung infections." ...tions in patients with non-cystic fibrosis-related bronchiectasis in Europe and India. The U.S. Food and Drug Admini...plans to expand this trial into the United States. bronchiectasis is the permanent widening of the bronchi (the larg...

Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing

...are on track to have Arikace Phase II clinical data in cystic fibrosis patients that have Pseudomonas lung infections this year. In addition, Phase II bronchiectasis data will be available in the first half of 2009," said Tim Whitten, President and Chief Executive Officer of Transave. Tim Whitten further commente...

Pharmaxis' First Steps into China

...clinical trial application for Bronchitol to treat bronchiectasis has been accepted for evaluation by China's State ...dicates that the number of Chinese who suffer from bronchiectasis is more than double that in the rest of the world....ory physicians have indicated they wish to conduct bronchiectasis studies, and have confirmed there is a large unmet...

Pharmaxis to Apply to Market Bronchitol in Australia

...rtson. "More than 20,000 Australians suffer from bronchiectasis and Pharmaxis expects Bronchitol to be the first t... years -- addressing an important medical need." bronchiectasis is an incurable, degenerative and chronic lung con...tal U.S. medical care expenditure is US$13,000 per bronchiectasis patient, double that of patients without the disor...

Pharmaxis Closes Share Purchase Plan

...c respiratory and immune disorders. Its development pipeline of products include, Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD) and PXS64 for the treatment of multiple sclerosis. Founded in 1998, Pharmaxis is listed on the Austr...
Other Tags
(Date:5/29/2015)... NJ (PRWEB) May 30, 2015 ... ever changing local and federal regulations, we provide ... of their patients who are suffering from pain, ... says Srinivas Nalamachu, MD, professor of rehabilitation medicine ... Institute in Overland Park, Kansas. , A new ...
(Date:5/29/2015)... M3 USA MDLinx.com, source of the ... specialties, now offers The Smartest Rheumatologist . The ... disorders ranging from Fibromyalgia and Osteoporosis, to Arthritis and ... MDLinx, and Caroline Tredway, editorial head of The Smartest ... have on the physicians who participate. Says Tredway, “With ...
(Date:5/29/2015)... The science of Follicular Unit Extraction ... more efficient methods of FUE hair transplantation have increased the ... the most cutting edge hair transplant methods being used to ... of extracting hair from the beard to the scalp. , ... correct male pattern baldness. Beard hair has a life ...
(Date:5/29/2015)... 29, 2015 Jan Wooden Howse lost her ... thing above all else: God does no wrong. , It’s ... her son’s passing is titled “God Does No Wrong.” It ... with great personal tragedy. , “My story has a ... to you into something productive, something healing,” Howse said. , ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 World Patent ... products, announces that it has signed a 10 year ... patent that aims to let people learn about any ... real time. , "This is an exciting day for ... said Scott J. Cooper, CEO and Creative Director of ...
Breaking Medicine News(10 mins):Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:MDLinx Launches Smartest Rheumatologist 2Health News:Beard to Scalp Hair Transplant: Newest Advance in Hair Transplant Technology 2Health News:Turning grief from a child’s passing into virtue 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5
(Date:5/26/2015)... DUBLIN , May 26, 2015 ... has announced the addition of the "Saudi ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... Saudi Arabia is projected to grow ... This high growth is attributed to the surging ...
(Date:5/22/2015)... DALLAS , May 22, 2015 ... Recognition Market by Solution (2D, 3D, Thermal, Emotion, Forensic), by ... End User (Government and Utilities, Consumer and Home) - ... Market to grow from $2.77 Billion in 2015 to ... Browse 79 market data Tables and ...
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
Other Contents